Kininogen Antibody

• Reactivity: Hu
• Applications: WB, IP
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

Kininogen Antibody Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human Kininogen
  Gln19-Ser644
  Accession # P01042
• Specificity: Detects human Kininogen in direct ELISAs and Western blots.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: KNG1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation 25 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Kininogen Antibody

• alpha 2-thiol Proteinase Inhibitor
• BDK
• BDK;BK;HAE6;HK;HMWK;Kininogen-1;KNG;KNG1
• Kininogen
• KNG1

Background

Kininogen, also known as alpha 2-thiol proteinase inhibitor, is a multi-function protein. There are two alternatively spliced forms, designated as the high molecular weight (HMW) and low MW (LMW) forms (1). The HMW form is synthesized as a 644 amino acid residue precursor with a signal peptide (residues 1‑18). The mature chain (residues 19‑644) is further processed into the heavy (residues 19‑380) and the light (residues 390‑644) chains. The active peptide bradykinin (residues 381‑389) is released, which has a variety of functions including muscle contraction, hypotension and inflammation. The heavy chain consists of three cystatin-like domains, which are responsible for inhibiting cysteine proteases. The light chain consists of a His-rich domain, which is associated with the clotting activity. In comparison to the HMW form, the LMW Kininogen (427 residues) has the same sequence in its heavy chain and bradykinin, but a different sequence in its light chain (residues 402‑427). The LMW form is not involved in blood clotting.

1. Takagaki, Y. et al. (1985) J. Biol. Chem. 260:8601.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Kininogen Antibody (AF1569)(3)

Publications using AF1569

• GK Annarapu, D Nolfi-Done, M Reynolds, Y Wang, L Kohut, B Zuckerbrau, S Shiva Heme stimulates platelet mitochondrial oxidant production to induce targeted granule secretion Redox Biology, 2021-12-05;48(0):102205. 2021-12-05 [PMID: 34891098] (Dot Blot, Human)
• Michael L. Merchant, Monika A. Niewczas, Linda H. Ficociello, Janice A. Lukenbill, Daniel W. Wilkey, Ming Li et al. Plasma kininogen and kininogen fragments are biomarkers of progressive renal decline in type 1 diabetes Kidney International 2013-06-01 [PMID: 23466993]
• Imamura T, Kobayashi H, Khan R, Nitta H, Okamoto K Induction of vascular leakage and blood pressure lowering through kinin release by a serine proteinase from Aeromonas sobria. J. Immunol., 2006-12-15;177(12):8723-9. 2006-12-15 [PMID: 17142774] (Western Blot, Human)

Bioinformatics

• Gene Symbol: KNG1
• Uniprot:
  • P01042()